At a glance
ClinicalIndex Comparison RecordN/ACompleted· 127 enrolled
Drug / intervention
CTAG Device with ACTIVE CONTROLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System
In Brief
An observational study evaluating CTAG Device with ACTIVE CONTROL for Thoracic Diseases. Completed, enrolled 127 participants across 20 sites in 7 countries.
Detailed Summary
Collect real-world clinical and device-specific outcomes of the GORE® TAG® Conformable Thoracic Stent Graft featuring ACTIVE CONTROL System (CTAG Device with ACTIVE CONTROL) in the treatment of aortic disease as part of routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThoracic Diseases
CountriesFrance, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionOct 2019
TodayJul 2026
First PostedSep 18, 2017
Enrollment StartOct 18, 2017
Primary CompletionOct 9, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.8 years ago
Interventions
CTAG Device with ACTIVE CONTROLdevice
Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.